Adicon offers GuardantOMNI® liquid biopsy test for clinical trials in China with equivalent performance to Guardant Health’s US-based laboratory test

April 2, 2024

HANGZHOU, China — Adicon Holdings Limited, a leading independent clinical laboratory company, announced today it now offers GuardantOMNI®, a 500-gene panel blood-based test, in addition to the Guardant360® liquid biopsy test, which will help to accelerate clinical trials and the research of targeted cancer drugs and immunotherapies in China. This test provides biopharmaceutical companies with access to comprehensive genomic profiling, also known as tumour mutation profiling, in patients with advanced solid cancers. Recently, its Shanghai Jince Medical Laboratory also successfully completed Analytical Validation (AV) Studies of Guardant Health’s GuardantOMNI test in China, confirming that the performance of the test in the Adicon laboratory is equivalent to Guardant Health’s US-based laboratory test.

“The Adicon laboratory is pleased to offer the GuardantOMNI test to local biopharmaceutical companies as it is a high-quality, comprehensive genomic profiling tool which can help accelerate clinical development programmes in immuno-oncology and targeted therapies in China,” said Song Gao, CEO of Adicon.

About Adicon
Adicon is one of the top three independent clinical laboratory, or ICL. We offer comprehensive and best-in-class testing services primarily to hospitals and health check centres as well as central laboratory services to biopharma clients and contract research organizations through an integrated network of 36 self-operated laboratories across China. Currently, we have 20 of our laboratories which are accredited by ISO15189, enabling us to provide customers with the quality assurance that comes with this rigorous international standard. Our testing portfolio consists of over 4,000 medical diagnostic tests, including
over 1,700 routine tests and over 2,300 esoteric tests. We are committed to continuously serving patients and the general public with our high-quality testing services as a leading ICL service provider in China and becoming a trusted and reliable partner for medical professionals and the general public.